Institution
American Cancer Society
Nonprofit•Atlanta, Georgia, United States•
About: American Cancer Society is a nonprofit organization based out in Atlanta, Georgia, United States. It is known for research contribution in the topics: Cancer & Population. The organization has 1339 authors who have published 3700 publications receiving 688166 citations. The organization is also known as: American Cancer Society, ACS & American Society for the Control of Cancer.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries collaborate annually to provide U.s. cancer information, this year featuring the first comprehensive compilation of cancer information for U.S. Latinos.
Abstract: BACKGROUND
The American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries collaborate annually to provide U.S. cancer information, this year featuring the first comprehensive compilation of cancer information for U.S. Latinos.
METHODS
Cancer incidence was obtained from 90% of the Hispanic/Latino and 82% of the U.S. populations. Cancer deaths were obtained for the entire U.S. population. Cancer screening, risk factor, incidence, and mortality data were compiled for Latino and non-Latino adults and children (incidence only). Long-term (1975–2003) and fixed-interval (1995–2003) trends and comparative analyses by disease stage, urbanicity, and area poverty were evaluated.
RESULTS
The long-term trend in overall cancer death rates, declining since the early 1990s, continued through 2003 for all races and both sexes combined. However, female lung cancer incidence rates increased from 1975 to 2003, decelerating since 1991 and breast cancer incidence rates stabilized from 2001 to 2003. Latinos had lower incidence rates in 1999–2003 for most cancers, but higher rates for stomach, liver, cervix, and myeloma (females) than did non-Latino white populations. Latino children have higher incidence of leukemia, retinoblastoma, osteosarcoma, and germ-cell tumors than do non-Latino white children. For several common cancers, Latinos were less likely than non-Latinos to be diagnosed at localized stages.
CONCLUSIONS
The lower cancer rates observed in Latino immigrants could be sustained by maintenance of healthy behaviors. Some infection-related cancers in Latinos could be controlled by evidence-based interventions. Affordable, culturally sensitive, linguistically appropriate, and timely access to cancer information, prevention, screening, and treatment are important in Latino outreach and community networks. Cancer 2006. Published 2006 by the American Cancer Society.
436 citations
••
TL;DR: There is a need to evaluate the effect of the screening program on the mortality of breast carcinoma, uncontaminated in the screening epoch by mortality from cases diagnosed in the prescreening period and cases diagnosed among unscreened women after the initiation of organized screening.
Abstract: The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties.
432 citations
••
TL;DR: In this population, postmenopausal estrogen use for 10 or more years was associated with increased risk of ovarian cancer mortality that persisted up to 29 years after cessation of use.
Abstract: ContextPostmenopausal estrogen use is associated with increased risk of endometrial
and breast cancer, 2 hormone-related cancers. The effect of postmenopausal
estrogen use on ovarian cancer is not established.ObjectivesTo examine the association between postmenopausal estrogen use and ovarian
cancer mortality and to determine whether the association differs according
to duration and recency of use.Design and SettingThe American Cancer Society's Cancer Prevention Study II, a prospective
US cohort study with mortality follow-up from 1982 to 1996.ParticipantsA total of 211 581 postmenopausal women who completed a baseline
questionnaire in 1982 and had no history of cancer, hysterectomy, or ovarian
surgery at enrollment.Main Outcome MeasureOvarian cancer mortality, compared among never users, users at baseline,
and former users as well as by total years of use of estrogen replacement
therapy (ERT).ResultsA total of 944 ovarian cancer deaths were recorded in 14 years of follow-up.
Women who were using ERT at baseline had higher death rates from ovarian cancer
than never users (rate ratio [RR], 1.51; 95% confidence interval [CI], 1.16-1.96).
Risk was slightly but not significantly increased among former estrogen users
(RR, 1.16; 95% CI, 0.99-1.37). Duration of use was associated with increased
risk in both baseline and former users. Baseline users with 10 or more years
of use had an RR of 2.20 (95% CI, 1.53-3.17), while former users with 10 or
more years of use had an RR of 1.59 (95% CI, 1.13-2.25). Annual age-adjusted
ovarian cancer death rates per 100 000 women were 64.4 for baseline users
with 10 or more years of use, 38.3 for former users with 10 or more years
of use, and 26.4 for never users. Among former users with 10 or more years
of use, risk decreased with time since last use reported at study entry (RR
for last use <15 years ago, 2.05; 95% CI, 1.29-3.25; RR for last use ≥15
years ago, 1.31; 95% CI, 0.79-2.17).ConclusionsIn this population, postmenopausal estrogen use for 10 or more years
was associated with increased risk of ovarian cancer mortality that persisted
up to 29 years after cessation of use.
428 citations
••
Harvard University1, Beth Israel Deaconess Medical Center2, Centro de Investigación y Docencia Económicas3, Pontifícia Universidade Católica do Rio Grande do Sul4, Universidade Federal do Rio Grande do Sul5, University of the Republic6, Union for International Cancer Control7, National Autonomous University of Mexico8, King's College London9, Pan American Health Organization10, Federal University of São Paulo11, University of Virginia12, University of Chicago13, Massachusetts Institute of Technology14, Johns Hopkins University School of Medicine15, Johns Hopkins University16, East Jefferson General Hospital17, Hoffmann-La Roche18, PATH19, University of Milan20, Hospital Maciel21, St. Jude Children's Research Hospital22, University of Tennessee Health Science Center23, International Atomic Energy Agency24, University of Buenos Aires25, University of São Paulo26, Universidad de La Sabana27, University of Texas MD Anderson Cancer Center28, University of Houston29, GlaxoSmithKline30, American Cancer Society31
TL;DR: In this article, the authors present the findings of their Cancer Commission and their recommendations to encourage Latin American stakeholders to redouble their efforts to address this increasing cancer burden and to prevent it from worsening and threatening their societies.
Abstract: Non-communicable diseases, including cancer, are overtaking infectious disease as the leading health-care threat in middle-income and low-income countries. Latin American and Caribbean countries are struggling to respond to increasing morbidity and death from advanced disease. Health ministries and health-care systems in these countries face many challenges caring for patients with advanced cancer: inadequate funding; inequitable distribution of resources and services; inadequate numbers, training, and distribution of health-care personnel and equipment; lack of adequate care for many populations based on socioeconomic, geographic, ethnic, and other factors; and current systems geared toward the needs of wealthy, urban minorities at a cost to the entire population. This burgeoning cancer problem threatens to cause widespread suffering and economic peril to the countries of Latin America. Prompt and deliberate actions must be taken to avoid this scenario. Increasing efforts towards prevention of cancer and avoidance of advanced, stage IV disease will reduce suffering and mortality and will make overall cancer care more affordable. We hope the findings of our Commission and our recommendations will inspire Latin American stakeholders to redouble their efforts to address this increasing cancer burden and to prevent it from worsening and threatening their societies.
418 citations
••
TL;DR: It is estimated that the breast cancer lifetime risks for the5% of BRCA1 carriers at lowest risk are 28%–50% compared to 81%–100% for the 5% at highest risk, and the ovarian cancer lifetime risk is 63% or higher, based on the known cancer risk-modifying loci.
Abstract: BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7 x 10(-8), HR = 1.14, 95% CI: 1.09-1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 x 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 x 10(-8), HR = 1.20, 95% CI: 1.17-1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 2 x 10(-4)). These loci may lead to an improved understanding of the etiology of breast and ovarian tumors in BRCA1 carriers. Based on the joint distribution of the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are 28%-50% compared to 81%-100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for BRCA1 carriers.
417 citations
Authors
Showing all 1345 results
Name | H-index | Papers | Citations |
---|---|---|---|
Walter C. Willett | 334 | 2399 | 413322 |
Meir J. Stampfer | 277 | 1414 | 283776 |
Frank B. Hu | 250 | 1675 | 253464 |
David J. Hunter | 213 | 1836 | 207050 |
Edward Giovannucci | 206 | 1671 | 179875 |
Irving L. Weissman | 201 | 1141 | 172504 |
Bernard Rosner | 190 | 1162 | 147661 |
Susan E. Hankinson | 151 | 789 | 88297 |
Paolo Boffetta | 148 | 1455 | 93876 |
Jeffrey A. Bluestone | 143 | 515 | 77080 |
Richard D. Smith | 140 | 1180 | 79758 |
Garth D. Illingworth | 137 | 505 | 61793 |
Brian E. Henderson | 137 | 712 | 69921 |
Ahmedin Jemal | 132 | 500 | 380474 |
Michael J. Thun | 129 | 392 | 79051 |